suvorexant
Sign in to saveSuvorexant, sold under the brand name Belsomra, is an orexin antagonist medication used in the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults. Suvorexant helps with falling asleep faster, sleeping longer, being awake less in the middle of the night, and having better quality of sleep. Its effectiveness is modest, and is similar to that of other orexin antagonists, but is lower than that of benzodiazepines and Z-drugs. Suvorexant is taken orally.
Key facts
- Drug.Verifiedfields
- verified
- Drug.Watchedfields
- verified
- Drug.verifiedrevid
- 458281672
- Drug.image
- Suvorexant.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Suvorexant-from-xtal-Mercury-3D-bs.png
- Drug.width
- 250px
- Drug.image_class2
- bg-transparent
- Drug.width2
- 250px
- Drug.tradename
- Belsomra
- Drug.MedlinePlus
- a614046
- Drug.DailyMedID
- Suvorexant
- Drug.pregnancy_AU
- B3
- Drug.dependency_liability
- Low
- Drug.addiction_liability
- Low
- Drug.routes_of_administration
- Oral
- Drug.class
- Orexin receptor antagonist; Hypnotic; Sedative
- Drug.ATC_prefix
- N05
via Wikipedia infobox
Research
548 papers- Suvorexant.2006
- Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis.Translational psychiatry · 2025
- Suvorexant.2012
- Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS.Annals of neurology · 2023
- Suvorexant for Reduction of Delirium in Older Adults After Hospitalization: A Randomized Clinical Trial.JAMA network open · 2024
via PubMed
Article
31 sectionsContents
- Medical uses
- Available forms
- Contraindications
- Side effects
- Overdose
- Interactions
- Pharmacology
- Pharmacodynamics
- Mechanism of action
- Pharmacokinetics
- Absorption
- Distribution
- Metabolism
- Elimination
- Specific populations
- Miscellaneous
- Chemistry
- History
- Society and culture
- Names
- Availability
- Legal status
- Controversy
- Research
- Delirium
- Psychiatry
- Alzheimer's disease
- Diabetes
- References
- Further reading
- External links
Suvorexant, sold under the brand name Belsomra, is an orexin antagonist medication used in the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults. Suvorexant helps with falling asleep faster, sleeping longer, being awake less in the middle of the night, and having better quality of sleep. Its effectiveness is modest, and is similar to that of other orexin antagonists, but is lower than that of benzodiazepines and Z-drugs. Suvorexant is taken orally.
Side effects of suvorexant include somnolence, daytime sleepiness and sedation, headache, dizziness, abnormal dreams, dry mouth, and impaired next-day driving ability. Rarely, sleep paralysis, sleep-related hallucinations, complex sleep behaviors like sleepwalking, and suicidal ideation may occur. Tolerance, dependence, withdrawal, and rebound effects do not appear to occur significantly with the medication. Suvorexant is a dual orexin receptor antagonist (DORA). It acts as a selective dual antagonist of the orexin OX1 and OX2 receptors. The medication has an intermediate elimination half-life of 12hours and a time to peak of about 2 to 3hours. Unlike benzodiazepines and Z-drugs, suvorexant does not interact with GABA receptors, instead having a distinct mechanism of action.